155 related articles for article (PubMed ID: 22155302)
1. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
2. Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences.
Vaishnavi K; Saxena N; Shah N; Singh R; Manjunath K; Uthayakumar M; Kanaujia SP; Kaul SC; Sekar K; Wadhwa R
PLoS One; 2012; 7(9):e44419. PubMed ID: 22973447
[TBL] [Abstract][Full Text] [Related]
3. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
Wadhwa R; Sugihara T; Yoshida A; Nomura H; Reddel RR; Simpson R; Maruta H; Kaul SC
Cancer Res; 2000 Dec; 60(24):6818-21. PubMed ID: 11156371
[TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of nuclear mortalin in human carcinogenesis.
Ryu J; Kaul Z; Yoon AR; Liu Y; Yaguchi T; Na Y; Ahn HM; Gao R; Choi IK; Yun CO; Kaul SC; Wadhwa R
J Biol Chem; 2014 Sep; 289(36):24832-44. PubMed ID: 25012652
[TBL] [Abstract][Full Text] [Related]
5. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
6. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regions.
Iosefson O; Azem A
FEBS Lett; 2010 Mar; 584(6):1080-4. PubMed ID: 20153329
[TBL] [Abstract][Full Text] [Related]
7. Functional significance of minor structural and expression changes in stress chaperone mortalin.
Deocaris CC; Widodo N; Ishii T; Kaul SC; Wadhwa R
Ann N Y Acad Sci; 2007 Nov; 1119():165-75. PubMed ID: 18056964
[TBL] [Abstract][Full Text] [Related]
8. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Sane S; Abdullah A; Nelson ME; Wang H; Chauhan SC; Newton SS; Rezvani K
Cell Stress Chaperones; 2016 Mar; 21(2):313-26. PubMed ID: 26634371
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
Nigam N; Grover A; Goyal S; Katiyar SP; Bhargava P; Wang PC; Sundar D; Kaul SC; Wadhwa R
PLoS One; 2015; 10(9):e0138192. PubMed ID: 26376435
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.
Pham MQ; Tran THV; Pham QL; Gairin JE
Fundam Clin Pharmacol; 2019 Aug; 33(4):385-396. PubMed ID: 30628118
[TBL] [Abstract][Full Text] [Related]
11. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.
Walker C; Böttger S; Low B
Am J Pathol; 2006 May; 168(5):1526-30. PubMed ID: 16651619
[TBL] [Abstract][Full Text] [Related]
12. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
13. Ashwagandha derived withanone targets TPX2-Aurora A complex: computational and experimental evidence to its anticancer activity.
Grover A; Singh R; Shandilya A; Priyandoko D; Agrawal V; Bisaria VS; Wadhwa R; Kaul SC; Sundar D
PLoS One; 2012; 7(1):e30890. PubMed ID: 22303466
[TBL] [Abstract][Full Text] [Related]
14. Induction of Senescence in Cancer Cells by a Novel Combination of Cucurbitacin B and Withanone: Molecular Mechanism and Therapeutic Potential.
Garg S; Huifu H; Kumari A; Sundar D; Kaul SC; Wadhwa R
J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1031-1041. PubMed ID: 31112603
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
Gestl EE; Anne Böttger S
Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
[TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of Mortaparib
Sari AN; Elwakeel A; Dhanjal JK; Kumar V; Sundar D; Kaul SC; Wadhwa R
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671256
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics-based identification of novel natural mortalin-p53 abrogators as anticancer agents.
Nagpal N; Goyal S; Dhanjal JK; Ye L; Kaul SC; Wadhwa R; Chaturvedi R; Grover A
J Recept Signal Transduct Res; 2017 Feb; 37(1):8-16. PubMed ID: 27380217
[TBL] [Abstract][Full Text] [Related]
18. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
19. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy.
Lu WJ; Lee NP; Kaul SC; Lan F; Poon RT; Wadhwa R; Luk JM
Cell Death Differ; 2011 Jun; 18(6):1046-56. PubMed ID: 21233847
[TBL] [Abstract][Full Text] [Related]
20. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
